Metastatic Clear Cell Renal Cell Carcinoma Clinical Trials

37 clinical trials for Metastatic Clear Cell Renal Cell Carcinoma across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk — RECRUITING · PHASE2
• Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial — RECRUITING · PHASE1
• Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma — RECRUITING · PHASE3
• Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) — RECRUITING · PHASE1
• Imaging of Solid Tumors Using 18F-TRX — RECRUITING · PHASE1
• Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer — RECRUITING · PHASE1
• Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer — RECRUITING · PHASE3
• VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma — RECRUITING · PHASE2
• Radiopharmaceutical Treatment of Advanced Kidney Cancer — RECRUITING · PHASE2
• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study — RECRUITING · PHASE2
• Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study — RECRUITING · PHASE2
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform — RECRUITING
• Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial — RECRUITING · PHASE3
• CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer — RECRUITING · PHASE1
• Imaging Study in Metastatic Clear Cell RCC. — NOT_YET_RECRUITING · PHASE1
• Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma — COMPLETED
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy — NOT_YET_RECRUITING · PHASE2
• Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial — NOT_YET_RECRUITING · PHASE2
• Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer — COMPLETED · PHASE1
• Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer — TERMINATED · PHASE2
• Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Had Received Prior Systemic Therapy — OTHER · PHASE3
• Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer — TERMINATED · PHASE1
• Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery — TERMINATED · PHASE2
• RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy — NOT_YET_RECRUITING · PHASE2
• PSMA Therapy and Immunotherapy in Kidney Cancer — WITHDRAWN · PHASE1
• [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma — OTHER · PHASE1
• 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma — OTHER · PHASE2
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) — COMPLETED · PHASE2
• Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma — TERMINATED · PHASE2
• Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery — TERMINATED · PHASE2
• High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer — COMPLETED · PHASE2
• Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma — COMPLETED · PHASE1
• A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma — TERMINATED · PHASE2
• Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer — COMPLETED · PHASE2

Refine this search